Deep Brain Stimulation for Parkinson Disease before L-dopa treatment: experience in three cases.
Objective: The goal of these case series is to investigate the possibility of deep brain stimulation (DBS) prior to L-dopa treatment in young Parkinsson…Predict Cognitive Decline with Clinical Markers in Parkinson’s Disease
Objective: We investigated which clinical-ready and cost-effective markers are predictive of cognitive impairment (CI) in Parkinson’s disease (PD) in a cohort of 294 patients with…Off-Target Implications of Nurr1 Agonist Therapy in Parkinson’s disease
Objective: To examine the impact of Nurr1 agonists on regulation of striatal Nurr1 and levodopa (LD)-induced dyskinesias (LIDs) in a rat model of Parkinson’s disease…The therapeutic effect of MANF in the MPTP/MPP+-induced model of Parkinson’s disease
Objective: To observe therapeutic effect of MANF in the attenuation of neurotoxin MPTP/MPP+-induced model of Parkinson's disease Background: Mesencephalic astrocyte-derived neurotrophic factor (MANF) is a…Synthesis and pharmacological evaluation of 16-aryldieno steroids as anti-parkinsonian agents in LPS induced Neuroinflammation Model of Rat
Objective: The present study is aimed at design and synthesis of new therapeutically useful steroidal neuroprotective derivatives as anti-parkinsonian agents. The new 16-aryldieno steroidal derivatives…Cinnamomum verum on Learning and Memory in Wistar Albino Rats
Objective: Several studies have been performed on Cinnamomum verum,but not much is known about the activity of Cinnamomum verum on Memory Enhancing.Therefore Cinnamomum verum is selected…Neuroprotective Potency of Tetrahydroisoquinoline a Novel Ayurveda Molecule in Experimental Parkinson’s Disease
Objective: Tetrahydroisoquinoline (TIQ) an identified alkaloid from ancient Indian ‘Ayurveda’ medicine for Parkinson’s disease (PD) was tested for neuroprotection in a cellular system and a…Multi-modal retention in a phase III clinical trial in early Parkinson disease (STEADY-PD III)
Objective: To evaluate novel retention strategies in an ongoing phase 3 clinical trial in individuals with Parkinson disease (PD) Background: Adequate participant retention is a…CB2R agonist AM1241 reverses the development of MPTP-induced PD and activates the regeneration of DA neurons
Objective: A promising and potential direction to treat PD is to develop new non-dopaminergic drugs without producing dyskinesia, as well as arresting and even reversing…AAV-mediated over-expression of VEGF-B in PINK1 gene knockout rats increases striatal dopamine content
Objective: To evaluate overexpression of the neuroprotective vascular endothelial growth factor B (VEGF-B) in a genetic Parkinson’s disease (PD) model. Background: We have shown in…
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- 13
- Next Page »